BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 24038106)

  • 21. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
    Seidel D; Shibina A; Siebert N; Wels WS; Reynolds CP; Huebener N; Lode HN
    Cancer Immunol Immunother; 2015 May; 64(5):621-34. PubMed ID: 25711293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining immunotherapy with high-dose radiation therapy (HDRT) significantly inhibits tumor growth in a syngeneic mouse model of high-risk neuroblastoma.
    Boboila S; Okochi S; Banerjee D; Barton S; Street C; Zenilman AL; Wang Q; Gartrell RD; Saenger YM; Welch D; Wu CC; Kadenhe-Chiweshe A; Yamashiro DJ; Connolly EP
    Heliyon; 2023 Jun; 9(6):e17399. PubMed ID: 37408891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition.
    Voeller J; Erbe AK; Slowinski J; Rasmussen K; Carlson PM; Hoefges A; VandenHeuvel S; Stuckwisch A; Wang X; Gillies SD; Patel RB; Farrel A; Rokita JL; Maris J; Hank JA; Morris ZS; Rakhmilevich AL; Sondel PM
    J Immunother Cancer; 2019 Dec; 7(1):344. PubMed ID: 31810498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
    Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
    Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.
    Cheng M; Ahmed M; Xu H; Cheung NK
    Int J Cancer; 2015 Jan; 136(2):476-86. PubMed ID: 24895182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma.
    Aiken TJ; Erbe AK; Zebertavage L; Komjathy D; Feils AS; Rodriguez M; Stuckwisch A; Gillies SD; Morris ZS; Birstler J; Rakhmilevich AL; Sondel PM
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.
    Song L; Ara T; Wu HW; Woo CW; Reynolds CP; Seeger RC; DeClerck YA; Thiele CJ; Sposto R; Metelitsa LS
    J Clin Invest; 2007 Sep; 117(9):2702-12. PubMed ID: 17710228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunization with a mimotope of GD2 ganglioside induces CD8+ T cells that recognize cell adhesion molecules on tumor cells.
    Wierzbicki A; Gil M; Ciesielski M; Fenstermaker RA; Kaneko Y; Rokita H; Lau JT; Kozbor D
    J Immunol; 2008 Nov; 181(9):6644-53. PubMed ID: 18941255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of anti-GD2 Antibody-producing Mesenchymal Stem Cells as Cellular Immunotherapy.
    Iguchi M; Yagyu S; Kambe K; Higashi M; Fumino S; Kishida T; Iehara T; Mazda O; Tajiri T
    Anticancer Res; 2023 Jun; 43(6):2417-2424. PubMed ID: 37247922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural antibody against neuroblastoma of TH-MYCN transgenic mice does not correlate with spontaneous regression.
    Kawakubo N; Harada Y; Ishii M; Souzaki R; Kinoshita Y; Tajiri T; Taguchi T; Yonemitsu Y
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1666-1673. PubMed ID: 30054041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.
    Taschner-Mandl S; Schwarz M; Blaha J; Kauer M; Kromp F; Frank N; Rifatbegovic F; Weiss T; Ladenstein R; Hohenegger M; Ambros IM; Ambros PF
    Oncotarget; 2016 Jan; 7(3):3571-86. PubMed ID: 26657295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma.
    Carlson LM; Rasmuson A; Idborg H; Segerström L; Jakobsson PJ; Sveinbjörnsson B; Kogner P
    Carcinogenesis; 2013 May; 34(5):1081-8. PubMed ID: 23349014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs.
    Terrile M; Bryan K; Vaughan L; Hallsworth A; Webber H; Chesler L; Stallings RL
    PLoS One; 2011; 6(12):e28356. PubMed ID: 22164278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.
    Zeng Y; Huebener N; Fest S; Weixler S; Schroeder U; Gaedicke G; Xiang R; Schramm A; Eggert A; Reisfeld RA; Lode HN
    Cancer Res; 2007 Mar; 67(5):2331-8. PubMed ID: 17332365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-15 Enhances Anti-GD2 Antibody-Mediated Cytotoxicity in an Orthotopic PDX Model of Neuroblastoma.
    Nguyen R; Moustaki A; Norrie JL; Brown S; Akers WJ; Shirinifard A; Dyer MA
    Clin Cancer Res; 2019 Dec; 25(24):7554-7564. PubMed ID: 31455682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.
    Yang RK; Kalogriopoulos NA; Rakhmilevich AL; Ranheim EA; Seo S; Kim K; Alderson KL; Gan J; Reisfeld RA; Gillies SD; Hank JA; Sondel PM
    Cancer Immunol Immunother; 2013 Aug; 62(8):1303-13. PubMed ID: 23661160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The glycosphingolipid GD2 as an effective but enigmatic target of passive immunotherapy in children with aggressive neuroblastoma (HR-NBL).
    Rovigatti U
    Cancer Lett; 2021 Apr; 503():220-230. PubMed ID: 33271265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma.
    Rasmuson A; Segerström L; Nethander M; Finnman J; Elfman LH; Javanmardi N; Nilsson S; Johnsen JI; Martinsson T; Kogner P
    PLoS One; 2012; 7(12):e51297. PubMed ID: 23284678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amphiregulin activates regulatory T lymphocytes and suppresses CD8+ T cell-mediated anti-tumor response in hepatocellular carcinoma cells.
    Yuan CH; Sun XM; Zhu CL; Liu SP; Wu L; Chen H; Feng MH; Wu K; Wang FB
    Oncotarget; 2015 Oct; 6(31):32138-53. PubMed ID: 26451607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MYCN repression of Lifeguard/FAIM2 enhances neuroblastoma aggressiveness.
    Planells-Ferrer L; Urresti J; Soriano A; Reix S; Murphy DM; Ferreres JC; Borràs F; Gallego S; Stallings RL; Moubarak RS; Segura MF; Comella JX
    Cell Death Dis; 2014 Sep; 5(9):e1401. PubMed ID: 25188511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.